A new cancer trial, designed to determine if current methods used in cancer screening can effectively decrease morbidity (illness) or mortality (death) from cancers of the prostate, lung, colon/rectum, and ovary (PLCO), is actively seeking participants. The PLCO Cancer Screening Trial is sponsored by the National Cancer Institute. Read all about the trial in today's Vidyya
On the subject of prostate cancer, we have two reports for you in today's issue. In the first report, the Technology Evaluation Center, an AHCPR Evidence-based Practice Center of the Blue Cross and Blue Shield Association, conducted a systematic review of the evidence from randomized controlled trials on the relative effectiveness
of alternative strategies for androgen suppression as treatment of advanced prostate cancer.
The second report regards screening recommendations for prostate cancer. Prostate cancer is the most common noncutaneous cancer in American men. After lung cancer, it accounts for more cancer deaths in men than any other single cancer site. Prostate cancer accounted for an estimated 244,000 new cases and 40,400 deaths in the U.S. in 1995. Risk increases with age, beginning at age 50, and is also higher among African American men.
In other prostate news, a nNational survey released today showed that only 15 percent of Americans have heard of prostatitis, a sometimes serious and often painful condition that will affect more than half of the male population at some point in their lives. Surprisingly, of those Americans who claimed to be knowledgeable about this disease, 16 percent believe that women and men were both affected by prostatitis.
And finally, A study in the August 2000, issue of Obstetrics and Gynecology (vol 96, No. 2; 207-213) shows that a new screening test which combines a blood test and an ultrasound exam can identify over 90% of
cases of Down syndrome in the first trimester of pregnancy.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.